证券代码：688246 证券简称：嘉和美康 公告编号：2023-030 嘉和美康（北京）科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 6 月 12 日(星期一) 至 6 月 16 日(星期五)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zqb@bjgoodwill.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年年度报告和 2023 年第一季度报告，为便于广大投资者更 全面深入地了解公司 2022 年度和 2023 年第一季度经营成果、财务状况，公司计 划于 2023 年 6 月 19 日(星期一) 下午 15:00-16:00 举行 2022 年度暨 2023 年第 一季度业绩 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥107,504,828.76, representing a year-on-year increase of 9.67%[5]. - The net profit attributable to shareholders was a loss of ¥22,660,220.88, with a basic and diluted earnings per share of -¥0.16[5][6]. - The company reported a net loss of CNY 146,704,762.57, compared to a loss of CNY 124,044,541.69 in the previous period[17]. - Net loss for Q1 2023 was CNY 31,354,681.56, an improvement from a net loss of CNY 37,033,436.97 in Q1 2022, representing a 15.5% reduction in losses[19]. - Operating profit for Q1 2023 was CNY -40,240,317.00, compared to CNY -45,205,360.05 in Q1 2022, indicating a narrowing of the operating loss by 11.5%[19]. - Basic and diluted earnings per share for Q1 2023 were both CNY -0.16, an improvement from CNY -0.20 in Q1 2022[20]. Cash Flow - The net cash flow from operating activities was -¥147,248,515.51, indicating a significant cash outflow[6]. - The net cash flow from operating activities was -147,248,515.51, compared to -157,222,315.08 in the previous period, indicating a slight improvement[23]. - Total cash outflow from operating activities amounted to 262,132,612.30, down from 280,736,232.75 year-over-year[23]. - Cash inflow from operating activities totaled CNY 114,884,096.79, down from CNY 123,513,917.67 in Q1 2022, a decrease of 6.4%[21]. - Cash inflow from investment activities was 87,948.75, while cash outflow was 5,694,232.70, resulting in a net cash flow from investment activities of -5,606,283.95[23]. - Cash inflow from financing activities totaled 18,000,000.00, while cash outflow was 97,378,156.05, leading to a net cash flow from financing activities of -79,378,156.05[24]. - The net increase in cash and cash equivalents was -232,233,333.39, compared to -376,593,809.95 in the previous period[24]. - The ending balance of cash and cash equivalents was 461,002,187.62, down from 832,554,512.54 year-over-year[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,406,098,639.73, down 4.79% from the end of the previous year[6]. - As of March 31, 2023, the total assets of the company amounted to CNY 2,406,098,639.73, a decrease from CNY 2,527,045,461.81 as of December 31, 2022, representing a decline of approximately 4.8%[15]. - The company's current assets totaled CNY 2,114,696,359.84, down from CNY 2,260,656,635.23, indicating a decrease of about 6.5%[16]. - Total liabilities decreased to CNY 589,600,672.88 from CNY 683,425,530.94, a reduction of about 13.8%[17]. - The company's equity attributable to shareholders decreased to CNY 1,792,133,661.32 from CNY 1,810,796,740.66, reflecting a decline of approximately 1%[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,549[11]. - The largest shareholder, Xia Nian, holds 24,690,198 shares, representing 17.91% of the total shares[11]. Research and Development - Research and development expenses totaled ¥53,749,878.60, accounting for 50.00% of operating revenue, a decrease of 3.08 percentage points[6]. - Research and development expenses for Q1 2023 were CNY 44,689,485.21, down from CNY 48,010,998.55 in Q1 2022, a decrease of 6.9%[18]. Other Financial Metrics - The weighted average return on equity was -1.26%[6]. - The company reported non-recurring gains of ¥1,777,752.68 after tax adjustments[9]. - The company did not conduct an audit for the Q1 financial statements[4]. - The company reported a decrease in tax and additional charges from CNY 1,021,007.99 in Q1 2022 to CNY 628,194.19 in Q1 2023, a reduction of 38.5%[18]. - Other income for Q1 2023 was CNY 4,144,253.89, slightly down from CNY 4,127,492.69 in Q1 2022, indicating a marginal decrease of 0.4%[18]. - Payments to employees amounted to 124,081,671.31, compared to 162,704,726.52 in the previous period, reflecting a decrease[23]. - Payments for taxes were 15,032,583.30, slightly lower than 15,547,461.96 in the previous period[23]. - The company reported cash payments for other operating activities totaling 34,209,101.98, down from 48,755,694.02 year-over-year[23]. - The company has adopted new accounting standards starting in 2023, which may affect the financial statements[24].

Financial Performance - The company reported a net loss of RMB 26,941,913.58 as of December 31, 2022, indicating that it does not meet the conditions for profit distribution in 2022 [6]. - The company has not declared any statutory surplus reserves or discretionary reserves for the year 2022 due to negative retained earnings [6]. - The company has not achieved profitability since its listing, as confirmed in the report [4]. - The company has not proposed any profit distribution plan for the reporting period due to the negative profit situation [6]. - The company's operating revenue for 2022 was CNY 716,948,756.64, representing a year-on-year increase of 9.97% compared to CNY 651,940,181.42 in 2021 [22]. - The net profit attributable to shareholders for 2022 was CNY 68,024,427.15, a significant increase of 37.13% from CNY 49,606,571.09 in 2021 [22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 53,829,864.75, a 37.00% increase from CNY 39,292,000.77 in 2021 [22]. - The net cash flow from operating activities decreased by CNY 61,729,038.95, primarily due to delayed customer payments and increased upfront investments in medical information projects [25]. - The weighted average return on equity decreased to 3.84% in 2022, down 6.73 percentage points from 10.57% in 2021 [23]. - The company reported a revenue of CNY 716.95 million for the year, representing a year-on-year increase of 9.97% [129]. - The operating cost for the year was CNY 350.57 million, which is a 10.21% increase compared to the previous year [129]. - The gross profit margin for the medical information industry was 51.12%, a decrease of 0.18 percentage points from the previous year [133]. Research and Development - Research and development expenses accounted for 24.71% of operating revenue in 2022, an increase of 5.47 percentage points from 19.24% in 2021 [23]. - The company achieved a total R&D investment of ¥177,152,231.62, representing a 41.24% increase compared to the previous year [90]. - The company applied for 18 new invention patents and received authorization for 8 during the reporting period, bringing the total number of authorized domestic invention patents to 28 [87][88]. - The company has developed 5 new core technologies that enhance medical data interoperability and utilization, bringing the total to 29 core technologies [82]. - The company’s R&D expenses increased by 26.60% to CNY 158.79 million, reflecting a significant investment in technology development [130]. - The number of R&D personnel is 687, accounting for 34.96% of the total workforce, with an average salary of $192,352.53, up from $122,312.27 in the previous period [107]. - Total compensation for R&D personnel increased to $132,146,190.77 from $84,640,092.32 in the previous period [107]. Market Position and Strategy - The company has maintained its position as the market leader in electronic medical record (EMR) systems in China for eight consecutive years, according to IDC data from 2014 to 2021 [72]. - The company has over 1,550 hospital clients, including more than 500 top-tier hospitals, representing over 25% of all top-tier hospitals in the country [72]. - The company ranks second in the Chinese medical big data solution market as of 2021, according to IDC [74]. - The company aims to become a leading player in the domestic medical informationization industry, focusing on clinical informationization and data application [170]. - The company plans to expand its product line by developing specialized electronic medical record systems and hospital data centers, addressing the pain points of large tertiary hospitals in data integration and utilization [173]. - The company has established a comprehensive customer acquisition and service network, achieving significant market share in its target market centered around tertiary hospitals [174]. Risks and Challenges - The company has detailed potential risks in the "Management Discussion and Analysis" section, emphasizing the importance of investor awareness regarding investment risks [7]. - The company faces risks related to changes in tax incentives, which could increase tax liabilities and negatively impact operating performance [124]. - The company is exposed to uncertainties in order acquisition and revenue growth due to varying levels of information technology needs among healthcare institutions [125]. - The company is at risk of increased bad debt losses due to rising accounts receivable and poor collection capabilities [122]. - The company is exposed to competitive risks in the medical informationization market, with increasing competition from new entrants [118]. Governance and Management - The company held its second extraordinary general meeting on July 15, 2022, where all proposed resolutions were approved without any rejections [181]. - The company plans to implement a stock option and restricted stock incentive plan for 2022, which was also approved in the second extraordinary general meeting [181]. - The company’s governance structure remains stable, with no significant changes reported in the red-chip structure [183]. - The company has established a remuneration assessment system for directors and senior management [199]. - The company has appointed several key personnel in management positions to strengthen its operational capabilities [192]. Future Outlook - The company expects a revenue guidance of 1.8 billion for the next fiscal year, indicating a growth target of 20% [188]. - The company plans to continue upgrading its intelligent comprehensive electronic medical record system and specialized electronic medical records to meet the long-term demand for intelligent, specialized, and customized solutions [173]. - Future efforts will focus on enhancing customer service efficiency and experience, increasing customer repurchase rates and value [174]. - The company will leverage policy support to penetrate and transform secondary hospitals and grassroots medical institutions, facilitating the implementation of hierarchical medical care reforms [174].

证券代码：688246 证券简称：嘉和美康 嘉和美康（北京）科技股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | |-----------------------|-------------------------------|---------------|----------------------------------------------------------------| | 投资者关系活动 \n类别 | □媒体采访 \n□现场参观 \n□其他 | | 特定对象调研 □分析师会议 \n□业绩说明会 \n□新闻发布会 □路演活动 | | | 华泰证券 | 范昳蕊 | | | | 嘉实基金 | 何鸣晓 | | | | 银河基金 | 沈怡 | | | | 新华资产 | 陈朝阳 | | | | 华商基金 | 刘力 | | | | 光大保德信基金 | | 安鹏 | | | 华泰柏瑞基金 | 杜聪 | | | 参与单位名称及 | 华泰柏瑞基金 | 陈碧野 | | | 人员姓名 | 国华人寿 | 安子超 | | | | 艾格基金 | Quinton ...

Financial Performance - Revenue for Q3 2022 reached ¥203,403,680.64, an increase of 16.77% year-over-year, while year-to-date revenue was ¥455,321,747.12, up 18.50%[5] - Net profit attributable to shareholders for Q3 2022 was ¥27,290,030.20, a significant increase of 497.42% compared to the same period last year[5] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥26,480,915.84, up 482.19% year-over-year[5] - Basic and diluted earnings per share for Q3 2022 were both ¥0.20, a substantial increase of 348.07% compared to the same period last year[6] - The net profit for the third quarter of 2022 was a loss of ¥18,939,625.90, an improvement from a loss of ¥35,853,138.66 in the same quarter of 2021[24] - The total comprehensive income attributable to the parent company for Q3 2022 was 1,475,893.23 CNY, compared to a loss of 22,578,714.32 CNY in the same period last year[25] - The company reported a total comprehensive loss of -18,939,625.90 CNY for Q3 2022, compared to a loss of -35,853,138.66 CNY in the previous year[25] Research and Development - Research and development expenses totaled ¥45,293,137.80 for Q3 2022, representing 22.27% of revenue, an increase of 3.59 percentage points from the previous year[6] - The company plans to continue its focus on research and development, with increased investment in personnel and projects[12] - Research and development expenses increased significantly to ¥135,334,064.77 in the first three quarters of 2022, compared to ¥96,437,052.14 in 2021, marking an increase of 40.4%[23] - The company’s financial performance indicates a strategic focus on R&D and cost management, as evidenced by the increase in R&D expenses and the reduction in net losses compared to the previous year[24] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥2,333,501,121.18, a decrease of 4.56% compared to the end of the previous year[6] - The company reported a total asset value of ¥2,333,501,121.18 as of the end of the third quarter of 2022, down from ¥2,444,869,042.34 at the end of the previous year[20] - Total liabilities decreased to ¥550,007,469.04 in the third quarter of 2022, compared to ¥650,266,679.24 in the same quarter of 2021[19] - The total equity attributable to shareholders of the parent company was ¥1,744,263,095.29, slightly up from ¥1,734,956,287.12 in the previous year[20] - The company recorded a significant increase in inventory, which rose to ¥500,029,818.48 from ¥400,778,242.85 year-over-year, indicating a growth of 24.8%[20] Cash Flow - The company reported a cash flow from operating activities of -¥288,844,282.25 for the year-to-date period[6] - The net cash flow from operating activities for the first three quarters of 2022 was -288,844,282.25 CNY, worsening from -209,569,438.54 CNY in the previous year[27] - Cash inflow from operating activities totaled 401,685,600.36 CNY, while cash outflow amounted to 690,529,882.61 CNY, resulting in a net cash outflow of 288,844,282.25 CNY[27] - The company reported cash and cash equivalents at the end of Q3 2022 of 555,579,181.95 CNY, down from 1,109,148,322.49 CNY at the beginning of the period[28] - Investment activities generated a net cash flow of -107,819,577.63 CNY, compared to -1,337,468.54 CNY in the same period last year[28] - The company raised 28,578,000.00 CNY from borrowings in Q3 2022, a significant decrease from 167,608,589.00 CNY in the previous year[28] - The total cash outflow from financing activities was 185,486,225.29 CNY, compared to 83,406,534.89 CNY in the same period last year[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,628[13] - The largest shareholder, Xia Jun, holds 24,690,198 shares, representing 17.91% of total shares[13] - The second-largest shareholder, Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, holds 19,569,619 shares, accounting for 14.19%[13] - The top ten shareholders collectively hold a significant portion of the company's shares, with the top three alone accounting for over 42%[14] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[15] Operational Insights - The report does not indicate any significant operational issues during the reporting period[16] - The company has not provided any future performance guidance or outlook in the current report[16] - There are no new product developments or market expansion strategies mentioned in the report[16]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 15%[19]. - The net profit attributable to shareholders for the same period was RMB 20 million, up 10% compared to the previous year[19]. - The company's operating revenue for the first half of the year was approximately CNY 251.92 million, representing a 19.94% increase compared to CNY 210.04 million in the same period last year[21]. - The net loss attributable to shareholders was CNY 25.81 million, a slight improvement from a loss of CNY 27.15 million in the previous year[21]. - The basic earnings per share for the period was -CNY 0.19, compared to -CNY 0.26 in the same period last year[20]. - The company has set a revenue guidance of RMB 220 million for the full year 2022, indicating a growth target of 18%[19]. - The company achieved operating revenue of 251.92 million yuan, representing a year-on-year growth of 19.94%[81]. - The company reported a net loss of ¥-216,016,793.03, compared to a loss of ¥-190,202,656.06 in the previous period, indicating a worsening of approximately 13.6%[171]. Research and Development - Research and development expenses increased by 30% to RMB 15 million, reflecting the company's commitment to innovation[19]. - Research and development expenses accounted for 40.97% of operating revenue, an increase of 10.55 percentage points from 30.42% in the previous year[20]. - Total R&D investment reached approximately ¥103.22 million, a year-on-year increase of 61.54%, with R&D expenses accounting for 40.97% of operating revenue, up from 30.42%[54][55]. - The number of employees engaged in research and development increased by 10.36% year-on-year, contributing to a significant rise in R&D spending[22]. - The company has a strong focus on original technology research and development in the healthcare information field, forming a proprietary technology and product system[48]. - The company has developed a core technology for medical big data that enhances data accuracy, consistency, and real-time responsiveness, achieving a leading level in the industry[50]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting tier-2 cities, expecting a 20% growth in user acquisition in these regions[19]. - The company plans to launch two new products in Q3 2022, aiming to capture an additional 5% market share in the healthcare sector[19]. - The company is exploring partnerships with international firms to enhance its technological capabilities and expand its product portfolio[19]. - The company is focused on expanding its market presence through new product development and technological advancements in healthcare information systems[60]. Product Development and Innovation - The company continues to focus on the development of medical information software, with a product portfolio that includes electronic medical record platforms and smart medical products[27]. - The electronic medical record platform has ranked first in the domestic niche market for eight consecutive years[30]. - The smart medical product system is driven by artificial intelligence and integrates real clinical data, covering multiple application scenarios such as clinical diagnosis and patient services[34]. - The company has developed an intelligent medical data platform that processes large-scale heterogeneous medical data, creating data models for various application scenarios[47]. Financial Position and Cash Flow - The net cash flow from operating activities decreased by CNY 120.70 million compared to the previous year, primarily due to pandemic-related disruptions and increased labor costs[22]. - The company's total assets decreased by 7.71% to CNY 2.26 billion from CNY 2.44 billion at the end of the previous year[21]. - The company reported a significant increase in prepayments, which rose by 47.09% to ¥125,418,796.97 from ¥85,264,869.40, reflecting the growth in business scale[105]. - The company reported a net cash outflow from operating activities of approximately -¥227.47 million, compared to -¥106.77 million in the previous year, indicating significant cash flow challenges[102]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[19]. - The company is exposed to macroeconomic risks, including potential impacts from natural disasters and pandemics, which could adversely affect its operations and revenue[100]. - The company faces uncertainties in order acquisition and revenue growth due to varying levels of information technology adoption among healthcare institutions, influenced by national policies[99]. Intellectual Property and Compliance - The company applied for 5 invention patents and received 5 invention patent authorizations during the reporting period, bringing the total number of domestic invention patents authorized to 25[53]. - The company holds 24 authorized invention patents and 748 software copyrights in the field of medical information technology[79]. - The company has not reported any violations or irregularities involving its directors, supervisors, senior management, or controlling shareholders during the reporting period[134]. Shareholder and Governance - The company has established measures to avoid competition with other enterprises controlled by its shareholders, ensuring compliance with fair market practices[132]. - The company emphasizes the importance of protecting investors' rights and has established a profit distribution policy, particularly regarding cash dividends, to ensure reasonable returns for investors[132]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period, reflecting good financial governance[133].

Financial Performance - The company reported a net loss of -38,792,427.91 RMB as of December 31, 2021, indicating that it does not meet the conditions for profit distribution in 2021[6]. - The company has not declared any statutory surplus reserves or discretionary reserves for the year 2021 due to negative retained earnings[6]. - The company has not proposed any profit distribution plan for the year 2021 due to the negative retained earnings situation[6]. - The company's operating revenue for 2021 was CNY 651,940,181.42, representing a year-on-year increase of 22.58% compared to CNY 531,837,003.60 in 2020[22]. - Net profit attributable to shareholders of the listed company reached CNY 49,636,904.83, a significant increase of 133.42% from CNY 21,265,425.26 in the previous year[22]. - The net cash flow from operating activities decreased by CNY 137,249,894.13, primarily due to the impact of the COVID-19 pandemic on client payment speeds and increased upfront investments in medical information projects[25]. - Total assets increased by 145.33% year-on-year to CNY 2,444,869,042.34, while net assets attributable to shareholders grew by 289.98% to CNY 1,734,956,287.12[25]. - The basic earnings per share for 2021 was CNY 0.48, up 128.57% from CNY 0.21 in 2020[23]. - The company reported a negative net cash flow from operating activities of -197.49 million yuan, primarily due to long project repayment cycles and high upfront costs[108]. - The company has cumulative undistributed losses of -38.79 million yuan in standalone reports and -190.20 million yuan in consolidated reports, affecting future profit distribution[109]. Governance and Compliance - The company has received a standard unqualified audit report from Dahua Certified Public Accountants[5]. - The company has confirmed that all board members attended the board meeting, ensuring governance compliance[5]. - The company has not violated any decision-making procedures in providing guarantees to external parties[8]. - The company has not reported any special arrangements in corporate governance[9]. - The company has maintained a stable management structure with no significant changes in shareholding among key personnel during the reporting period[164]. - The company reported no changes in shareholding for independent directors and supervisors during the reporting period, with each receiving a pre-tax compensation of 6.00 million yuan[163]. - The company did not receive any penalties from securities regulatory agencies in the past three years[178]. Research and Development - The company invested 19.24% of its operating revenue in research and development, an increase of 1.89 percentage points from 17.35% in 2020[24]. - R&D investment totaled 125.43 million yuan, a year-on-year increase of 35.93%, with R&D personnel growing by 15.72%[33]. - The significant increase in R&D investment is attributed to the company's continued commitment to enhancing R&D efforts[78]. - The company applied for 40 invention patents during the reporting period and received 6 invention patent authorizations, bringing the total to 20 authorized invention patents by December 31, 2021[74]. - The company has developed 24 core technologies in the medical information field, with 21 of them applied to electronic medical records, hospital data centers, smart healthcare, and internet healthcare[70]. Market Position and Strategy - The company was recognized as a "Little Giant" enterprise by the state, reflecting its innovation and market position[31]. - The company has maintained its position as the market leader in electronic medical records (EMR) in China, ranking first for seven consecutive years from 2014 to 2020 according to IDC data[62]. - The company aims to become a leading player in the domestic medical information industry, focusing on clinical informationization and digital transformation[152]. - The company is focused on innovation, with core technical personnel involved in multiple technology-related firms, indicating a commitment to research and development[172]. - The company is exploring partnerships to leverage synergies in technology and market access[1]. Product Development and Innovation - The company launched several new products, including an integrated emergency platform and a VTE risk prevention system, enhancing its product offerings[36][37]. - The company has developed a comprehensive electronic medical record system for dental specialties, covering all current dental professional fields, enhancing daily diagnosis and treatment efficiency[48]. - The company is developing a one-stop research analysis platform to meet comprehensive research needs, including data retrieval and statistical analysis[154]. - The company has successfully launched multiple innovative product lines, including emergency and obstetric specialized electronic medical records, to meet the urgent demand for data integration and reuse[154]. Financial Health and Risks - The company faces risks from uncontracted project implementations, with costs of 71,000 yuan recognized without corresponding revenue due to inability to sign contracts[104]. - Inventory increased significantly, with a provision for inventory impairment of 14.62 million yuan, indicating potential risks if project contracts do not cover costs[109]. - The company is exposed to seasonal performance fluctuations, with significant revenue recognition occurring in the second half of the year, particularly in Q4[106]. - Changes in tax incentives could adversely affect the company's financial performance, as it currently benefits from reduced corporate income tax rates[110]. - The company is exposed to macroeconomic risks, including potential impacts from natural disasters and the resurgence of COVID-19, which could affect business operations[113]. Employee and Management Structure - The company has a total of 1,983 employees, with 54 in the parent company and 1,929 in major subsidiaries[186]. - The company has 692 R&D personnel, representing 34.90% of the total workforce, with an average salary of CNY 122,312.27[94]. - The overall compensation for the management team reflects a focus on retaining talent while ensuring stability in leadership roles[164]. - The company emphasizes a competitive and equitable salary structure, aligning with market conditions and employee performance[187]. Future Outlook - The company provided guidance for the next fiscal year, projecting revenue growth of 10% to 12%[168]. - The company plans to implement a new customer engagement strategy aimed at improving user retention by 15%[168]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share within the next two years[168]. - The company remains optimistic about future growth, driven by strong market demand and innovative product offerings[165].

Financial Performance - The company's operating revenue for Q1 2022 was ¥98,027,811.38, representing a year-on-year increase of 33.94%[5]. - The net profit attributable to shareholders was a loss of ¥27,858,515.60, with a year-on-year decrease of ¥7,689,251.04 due to increased personnel costs[5][8]. - The company reported a net loss of RMB 218,061,171.66, compared to a loss of RMB 190,202,656.06 in the previous year[16]. - The net profit attributable to the parent company was -27,858,515.60 CNY, compared to -20,169,264.57 CNY in the same period last year, reflecting a decline of approximately 38.5%[19]. - The company’s operating profit was -45,205,360.05 CNY, worsening from -30,267,249.92 CNY in the same quarter last year, indicating a decline of approximately 49.5%[18]. - The company reported a total comprehensive income of -37,033,436.97 CNY, compared to -24,924,223.17 CNY in the same quarter last year, marking an increase in losses of about 48.8%[19]. - The company's basic and diluted earnings per share were both -0.20 CNY, unchanged from the previous year[19]. Research and Development - Research and development (R&D) expenses totaled ¥52,032,614.41, which is an increase of 72.57% compared to the previous year, accounting for 53.08% of operating revenue, up by 11.88 percentage points[6][8]. - The company experienced a significant increase in R&D personnel, contributing to higher R&D costs[8]. - Research and development expenses rose to 48,010,998.55 CNY, up from 30,151,889.52 CNY, indicating a growth of approximately 59.4%[18]. Cash Flow and Assets - The net cash flow from operating activities was a negative ¥157,222,315.08, indicating challenges in cash collection from clients[6][8]. - The net cash flow from operating activities was -157,222,315.08 CNY, worsening from -93,764,377.91 CNY in the previous year[22]. - Cash and cash equivalents decreased to RMB 894,427,940.60 from RMB 1,273,521,765.55, representing a decline of approximately 30% year-over-year[14]. - The cash and cash equivalents at the end of the period were 832,554,512.54 CNY, down from 1,209,148,322.49 CNY at the beginning of the period, a decrease of approximately 31.1%[23]. - Total assets at the end of the reporting period were ¥2,230,348,720.37, down 8.77% from the end of the previous year[6]. - The company's total assets were RMB 2,230,348,720.37, down from RMB 2,444,869,042.34, showing a decrease of around 9%[16]. - Total current assets amounted to RMB 2,025,025,787.00, down from RMB 2,269,015,610.12, indicating a decrease of about 11%[14]. - Total liabilities decreased to RMB 472,779,794.24 from RMB 650,266,679.24, a reduction of about 27%[16]. - The total equity attributable to shareholders decreased to RMB 1,707,097,771.52 from RMB 1,734,956,287.12, a decline of about 2%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,726[10]. - The top shareholder, Xia Jun, holds 17.91% of the shares, totaling 24,690,198 shares[10][11]. Operating Costs - The total operating costs increased to 150,663,048.75 CNY from 106,343,310.91 CNY, representing an increase of about 41.7% year-over-year[18]. - The company incurred a financial expense of -2,007,438.46 CNY, compared to a financial income of 750,564.06 CNY in the previous year, indicating a significant shift in financial performance[18]. Sales Performance - The total revenue from sales of goods and services was 105,143,461.21 CNY, an increase from 99,973,624.84 CNY year-over-year, reflecting a growth of about 5.2%[21]. Market and Product Development - The company has not disclosed any new product developments or market expansion strategies in the current report[13].